About
Protein therapeutics for lung disorders
Areas of Focus
Categories
Biologics & BiopharmaceuticalSoutheastern U.S.
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
408
By Phase
PHASE2/PHASE3: 1PHASE1: 2
By Status
ACTIVE_NOT_RECRUITING: 1COMPLETED: 1TERMINATED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06897839Lead Sponsor
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
PHASE2/PHASE3Active, not recruiting
366 participants
Started: Feb 3, 2025 · Completed: Feb 28, 2030
NCT04662151Lead Sponsor
A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)
PHASE1Completed
37 participants
Started: Sep 1, 2021 · Completed: May 29, 2024
NCT04659122Lead Sponsor
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
PHASE1Terminated
5 participants
Started: Aug 17, 2021 · Completed: Feb 23, 2023
Funding History (1)
D
Mar 13, 2018
Locations (1)
Headquarters
Marietta, GA, United States
Map
Loading map...